8:31 am Gilead Sciences announces the FDA has granted priority review to the co’s NDA for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir 400 mg
View todays social media effects on GILD
View the latest stocks trending across Twitter. Click to view dashboard
See who Gilead is hiring next, click here to view
